GlassScriptPhysician profile
Gregory B Caudill
NPI 1477718013
$8,726.56
in general payments reported to CMS, 2019-2025
9 companies · $411 in 2025
The $411 reported for 2025 was more than what 76% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $104 · 2021: $75.46 · 2022: $470 · 2023: $6,921 · 2024: $416 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,430 · Food and Beverage: $1,616 · Travel and Lodging: $687 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,430.00 |
| Food and Beverage | $1,616.14 |
| Travel and Lodging | $687.17 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,112.52 | 2019-2023 | |
| Braeburn INC. | $741.94 | 2023-2025 | Brixadi |
| Alkermes, INC. | $297.37 | 2019-2025 | Vivitrol, Vivitrol |
| Indivior INC. | $221.12 | 2019-2025 | Sublocade |
| Orexo US, INC. | $133.20 | 2020-2023 | Zubsolv |
| Mdd US Operations, LLC | $102.38 | 2019 | |
| Alfasigma USA, INC. | $63.11 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Abbvie INC. | $19.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Caudill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.